MeiraGTx Holdings Stock Discussion

$MeiraGTx Holdings (MGTX.US)$ Reuters· just
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Aav2-Haqp1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

$MeiraGTx Holdings (MGTX.US)$
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX) announced five poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress in Rome, Italy. The posters highlight the company's advancements in genetic medicine and cell therapy platforms:
1. Optimized AAV manufacturing platform yielding high titers and improved product quality.
2....

$MeiraGTx Holdings (MGTX.US)$
MeiraGTx Holdings | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(8.6%),Johnson & Johnson Innovation-JJDC, Inc.(8.6%)

$Amazon (AMZN.US)$ breaking news big $Meiragtx Holdings Plc just cured Parkinson disease treatment 🔥🔥🔥👀 news today

$MeiraGTx Holdings (MGTX.US)$ Reuters· 3 mins ago
MeiraGTx Holdings PLC: Primary Study Objective of Safety and Tolerability Was Met

$MeiraGTx Holdings (MGTX.US)$ MeiraGTx Announces $50 Million Offering of Ordinary Shares Led by Sanofi’s 30M and Reports Second Quarter 2024 Financial and Operational Results

$MeiraGTx Holdings (MGTX.US)$
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi -4/sh
MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage genetic medicine company, has announced the pricing of an underwritten offering of 12,500,000 ordinary shares at $4.00 per share. The offering, expected to close on August 13, 2024, aims to raise $50 million in gross proceeds. Sanofi led the financing with a $30 million equity investment, joined by Perceptive Advisors and other inst...

$MeiraGTx Holdings (MGTX.US)$ MeiraGTx to Participate in Upcoming Investor Conferences 2 MINUTES AGO, 4:30 PM EDT VIA GLOBENEWSWIRE    LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Chardan 8th Annual Genetic Medicines ...